Journal reading
Long-term prescribing of new oral anticoagulants
Warfarin and the new oral anticoagulants are licensed for non-valvular atrial fibrillation and venous thromboembolism. The choice of anticoagulant depends on the characteristics of the patient and the medicine.
-
Cost: free
Paul KL Chin, Aust Prescr 2016;39:200-4
Accreditation
This activity should take approximately 1 hour to complete. It can be included in a pharmacist’s CPD Plan for either one Group 1 credit or, on successful completion of the assessment activity, two Group 2 credits. Pharmacists should self-record this activity for CPD purposes.
Pharmacy Competency Standards
- 1.4 Manage quality and safety
- 4.2 Consider the appropriateness of prescribed medicines
- 7.1 Contribute to therapeutic decision making
- 7.2 Provide ongoing medication management
About
This activity has been designed to take around 1 hour to complete - this is based on reading the article from an issue of Australian Prescriber and completing a quiz. You will be provided with immediate feedback on your answers and a certificate of completion will be available for you to download for self-reporting purposes.
Learning objectives
- Define circumstances where warfarin would be more appropriate than the new oral anticoagulants.
- Comprehend the pharmacokinetics of the new oral anticoagulants.
- Define factors that affect the dose of the new oral anticoagulants.
- Identify potential drug interactions with the new oral anticoagulants.
- Relate what monitoring is required with the new oral anticoagulants.
